At the 18th Annual Ambulatory Surgery Centers Conference in Chicago on Oct. 28, Kate Lovrien, senior manager, and Luke Peterson, national director of the strategy group, Kurt Salmon Associates, ...
CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million people in the U.S. alone In prior studies, CBT-004 demonstrated an ...
SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate ...
PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (CGTX), (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...
The life sciences company reported it has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its Phase 3 clinical trial, IMPACT DUCHENNE, for SGT-003. The FDA agreed ...
IMUNON announced FDA alignment on CMC strategy for IMNN-001, preparing for a Phase 3 trial in advanced ovarian cancer. IMUNON, Inc. announced a successful Type C Chemistry, Manufacturing, and Controls ...
(RTTNews) - Diamyd Medical announced that it has reached alignment with the U.S. Food and Drug Administration to accelerate the primary efficacy readout in its ongoing pivotal, registrational Phase 3 ...
- Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Development - ALPHARETTA, Ga., March 06, 2025 (GLOBE ...
"This alignment represents an important step forward and underscores the potential to address a significant unmet medical need in patients with neuropathic corneal pain," said Raj Patil, Chief ...